Hotline 24/7: 0909384389

Share links:

P2Y12 inhibitor monotherapy associated with increased risk of cardiac death after PCI

Ngày 02/07/2020 09:11 | Lượt xem: 1132

A subanalysis of the Onyx One study found that cardiac death was significantly higher in patients who received single antiplatelet therapy with a P2Y12 inhibitor following percutaneous coronary intervention (PCI) than those who received single antiplatelet therapy with aspirin. Furthermore, single antiplatelet therapy with a P2Y12 inhibitor was a predictor of the combined endpoint of cardiac death/myocardial infarction/stent thrombosis between one and 12 months.

Speaking during PCR eCourse 2020, Azeem Latib (Department of Cardiology, Montefiore Medical Center, New York, USA) reported that the Onyx One trial was a prospective multicentre, randomised controlled trial (with 2,000 patients enrolled) that found “Resolute Onyx [Medtronic] is safe and effective in complex high bleeding risk patients who receive one-month dual antiplatelet therapy [DAPT]”. He added that the aim of the present analysis was to review if there were any differences between in outcomes at one-year between those who received single antiplatelet therapy with aspirin and those who received single antiplatelet therapy with a P2Y12 inhibitor (after discontinuation of DAPT at one month). The primary endpoint, as in the main study, was the rate of cardiac death, myocardial infarction, or stent thrombosis at one year.

“In this subanalysis, we combined the stent groups [the comparator in the study was BioFreedom, Biosensors] and then stratified patients in into two groups depending on which antiplatelet therapy they were taking—so either aspirin monotherapy or P2Y12 monotherapy,” Latib explained. Overall, of those on single antiplatelet therapy at two months after PCI (92% of patients), 56% were on aspirin and 44% were on a P2Y12 inhibitor (predominantly clopidogrel)—the choice between aspirin and a P2Y12 inhibitor was at the operator’s discretion.

According to Latib, there were significant differences between groups in terms of patient characteristics. P2Y12 patients had more atrial fibrillation, more concomitant oral anticoagulation use, and more often met the high bleeding risk criteria while more aspirin patients had renal failure and more myocardial infarction. There were no significant differences in lesion characteristics between groups.

Overall, the rate of the combined endpoint of cardiac death/myocardial infarction/stent thrombosis between one and 12 months did not differ between groups. However, cardiac death was significantly increased in the P2Y12 inhibitor group. “It is not really apparent why this difference occurred, particularly as patients in this group had a lower rate of myocardial infarction compared with patients in the aspirin group. They had a similar rate of stroke/death thrombosis and also a numerical lower rate of bleeding,” Latib observed.

To further investigate the apparent link between cardiac death and P2Y12 inhibitor monotherapy therapy, Latib and colleagues performed a Kaplan-Meier analysis. They again found no significant differences between groups in the combined endpoint but still found a difference in cardiac death (increased with the P2Y12 inhibitor). “We performed a multivariate cox aggression to try to identify what the potential predictors of cardiac death/myocardial infarction/stent thrombosis, between one and 12 months, were… choice of single antiplatelet therapy seemed to be an important risk factor,” he noted.

Concluding, Latib said: “Adverse ischaemic and bleeding rates between one and 12 months were similar irrespective of the single antiplatelet agent that was continued, except for cardiac death which was higher with P2Y12 inhibitors”. He added that further analyses “will expand the dataset with the ONYX Clear study patients”.

Source CardiovascularNews

Duc Tin Clinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support